Trials (Riga Eastern Clinical University Hospital)

forpatients forresearchers forproviders latviacountry Go back to Riga Eastern Clinical University Hospital page

Trials: How to participate

Contact information: Click here to access.

NCTID: NCT01903733

Title: Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 
Study Summary: The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint. 
Sponsor: Pfizer 
Intervention: bosutinib 
Start Date: 2013-08-28 
Last Updated: 2022-07-19 
Number of Patients: 281 
Recruitment Status: COMPLETED 
Condition: Chronic Myeloid Leukemia 

NCTID: NCT03425643

Title: Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) 
Study Summary: This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery <math display="block">neoadjuvant phase</math>, followed by pembrolizumab alone after surgery <math display="block">adjuvant phase</math> in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS). 
Sponsor: Merck Sharp & Dohme LLC 
Intervention: Pembrolizumab 
Start Date: 2018-04-24 
Last Updated: 2023-11-13 
Number of Patients: 797 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Non-small Cell Lung Cancer 

NCTID: NCT04464226

Title: Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer 
Study Summary: The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor’s visits as often as they did in the previous study. 
Sponsor: Bayer 
Intervention: Darolutamide (Nubeqa, BAY1841788) 
Start Date: 2020-10-20 
Last Updated: 2023-11-18 
Number of Patients: 678 
Recruitment Status: RECRUITING 
Condition: Cancer 

NCTID: NCT00910091

Title: The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer 
Study Summary: This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer. 
Sponsor: Ipsen 
Intervention: BN83495 
Start Date: 2009-08 
Last Updated: 2019-01-30 
Number of Patients: 73 
Recruitment Status: COMPLETED 
Condition: Endometrial Cancer 

NCTID: NCT02425891

Title: A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) 
Study Summary: This multicenter, randomized, double-blind study evaluated the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents. 
Sponsor: Hoffmann-La Roche 
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody 
Start Date: 2015-06-23 
Last Updated: 2022-07-19 
Number of Patients: 902 
Recruitment Status: COMPLETED 
Condition: Triple Negative Breast Cancer 

NCTID: NCT05171049

Title: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE 
Study Summary: This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER) 
Sponsor: Anthos Therapeutics, Inc. 
Intervention: Abelacimab 
Start Date: 2022-05-05 
Last Updated: 2023-11-21 
Number of Patients: 1655 
Recruitment Status: RECRUITING 
Condition: Venous Thromboembolism 

NCTID: NCT01018953

Title: Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome 
Study Summary: The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment. 
Sponsor: Ipsen 
Intervention: BIM 23A760 
Start Date: 2010-02 
Last Updated: 2020-11-20 
Number of Patients: 8 
Recruitment Status: TERMINATED 
Condition: Carcinoid Syndrome 

NCTID: NCT02106546

Title: Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer 
Study Summary: The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC). 
Sponsor: AbbVie 
Intervention: Carboplatin 
Start Date: 2014-04-10 
Last Updated: 2020-11-17 
Number of Patients: 970 
Recruitment Status: COMPLETED 
Condition: Squamous Non-Small Cell Lung Cancer 

NCTID: NCT00545129

Title: A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone 
Study Summary: The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone. 
Sponsor: Pfizer 
Intervention: Tanezumab 10 mg IV 
Start Date: 2009-04-29 
Last Updated: 2021-06-18 
Number of Patients: 59 
Recruitment Status: COMPLETED 
Condition: Neoplasm Metastasis 

NCTID: NCT04961996

Title: A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) 
Study Summary: This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.  In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination with abemaciclib in a subset of the primary study population. 
Sponsor: Hoffmann-La Roche 
Intervention: Giredestrant 
Start Date: 2021-08-27 
Last Updated: 2023-11-18 
Number of Patients: 4200 
Recruitment Status: RECRUITING 
Condition: Early Breast Cancer 

NCTID: NCT00440310

Title: Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases 
Study Summary: The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver metastases, and to demonstrate the safety of Litx™ therapy.  Litx™ consists of a light-activated drug, talaporfin sodium (LS11, Light Sciences Oncology, Bellevue, Washington), and a light generating device, composed of light-emitting diodes (LEDs), that is energized by a power controller and percutaneously placed in the target tumor tissue inside the body. 
Sponsor: Light Sciences Oncology 
Intervention: Talaporfin sodium 
Start Date: 2007-02 
Last Updated: 2015-08-25 
Number of Patients: 483 
Recruitment Status: COMPLETED 
Condition: Liver Metastases 

NCTID: NCT00707304

Title: Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer 
Study Summary: The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens. 
Sponsor: Agennix 
Intervention: Talactoferrin 
Start Date: 2008-11 
Last Updated: 2012-08-21 
Number of Patients: 742 
Recruitment Status: COMPLETED 
Condition: Non Small Cell Lung Cancer 

NCTID: NCT00915018

Title: Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer 
Study Summary: This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will also compare the safety of the two regimens and as well as the quality of life of subjects receiving either regimen. 
Sponsor: Puma Biotechnology, Inc. 
Intervention: Neratinib 
Start Date: 2009-08-21 
Last Updated: 2018-08-22 
Number of Patients: 479 
Recruitment Status: COMPLETED 
Condition: Breast Cancer 

NCTID: NCT02163694

Title: A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer 
Study Summary: The primary objective of the study is to assess the progression-free survival (PFS) of veliparib in combination with carboplatin and paclitaxel (C/P) compared to placebo plus C/P in participants with a Breast Cancer Gene 1 or 2 (BRCA1; BRCA2) mutation in Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic or locally advanced unresectable breast cancer. The secondary objectives of the study are to assess overall survival (OS), clinical benefit rate (CBR) through the end of Week 24, objective response rate (ORR) and PFS on subsequent therapy (PFS2) in participants treated with veliparib in combination with C/P versus placebo in combination with C/P. 
Sponsor: AbbVie 
Intervention: Veliparib Placebo 
Start Date: 2014-07-17 
Last Updated: 2023-02-16 
Number of Patients: 509 
Recruitment Status: ACTIVE_NOT_RECRUITING 
Condition: Metastatic Breast Cancer 

NCTID: NCT02657434

Title: A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) 
Study Summary: This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase. 
Sponsor: Hoffmann-La Roche 
Intervention: Atezolizumab 
Start Date: 2016-04-30 
Last Updated: 2023-11-21 
Number of Patients: 578 
Recruitment Status: COMPLETED 
Condition: Non-Small Cell Lung Cancer 

NCTID: NCT00600340

Title: 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab 
Study Summary: First-line treatment of patients with locally recurrent or metastatic, HER2-negative breast cancer who have not received prior chemotherapy for locally recurrent or metastatic disease. 
Sponsor: Central European Cooperative Oncology Group 
Intervention: Bevacizumab and Paclitaxel 
Start Date: 2008-04 
Last Updated: 2019-12-30 
Number of Patients: 564 
Recruitment Status: COMPLETED 
Condition: Metastatic Breast Cancer 

NCTID: NCT05353257

Title: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer 
Study Summary: This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer. 
Sponsor: Shanghai Henlius Biotech 
Intervention: Serplulimab 
Start Date: 2022-05-17 
Last Updated: 2023-10-10 
Number of Patients: 482 
Recruitment Status: RECRUITING 
Condition: Limited-Stage Small Cell Lung Cancer 

NCTID: NCT03033511

Title: A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) 
Study Summary: This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy. 
Sponsor: AbbVie 
Intervention: Placebo for dexamethasone 
Start Date: 2017-02-07 
Last Updated: 2021-07-29 
Number of Patients: 748 
Recruitment Status: TERMINATED 
Condition: Small Cell Lung Cancer

hasCancerType::C00-D48: All neoplasms hasCancerType::C00-C97: All cancer types hasCancerType::C00-C14: Mouth/throat cancers hasCancerType::C15-C26: Digestive system cancers hasCancerType::C30-C39: Lung/chest cancers hasCancerType::C40-C41: Bone cancers hasCancerType::C43-C44: Skin cancers/melanoma hasCancerType::C45-C49: Soft tissue cancer hasCancerType::C50: Breast cancer hasCancerType::C51-C58: Female genitalia cancers hasCancerType::C60-C63: Male genitalia cancer hasCancerType::C64-C68: Urinary system cancers hasCancerType::C69-C72: Eye and brain cancer hasCancerType::C73-C75: Thyroid and other gland cancers hasCancerType::C76-C80: Cancers of unknown or unspecified areas hasCancerType::C81-C96: Cancers of the blood and immune system hasCancerType::C97-C97: Cancers in multiple locations from the start hasCancerType::D00-D09: Early-stage cancers not yet spread hasCancerType::D10-D36: Benign tumour hasCancerType::D37-D48: Growths of uncertain nature hasCancerType::unknown isTrial